[HTML][HTML] Prescribing patterns of proprotein convertase subtilisin-kexin type 9 inhibitors in eligible patients with clinical atherosclerotic cardiovascular disease or …
DG Karalis, UG Mallya, AF Ghannam, J Elassal… - The American journal of …, 2018 - Elsevier
Two proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors are approved for
patients with atherosclerotic cardiovascular disease or heterozygous familial …
patients with atherosclerotic cardiovascular disease or heterozygous familial …
[HTML][HTML] Drugs for hypercholesterolaemia–from statins to pro-protein convertase subtilisin kexin 9 (PCSK9) inhibition
AS Wierzbicki, P Grant - Clinical Medicine, 2016 - Elsevier
Cardiovascular disease (CVD) remains one of the commonest sources of morbidity and
mortality in the world. Lipids and especially low density lipoprotein cholesterol (LDL-C) …
mortality in the world. Lipids and especially low density lipoprotein cholesterol (LDL-C) …
Efficacy and safety of different dosing regimens of alirocumab (starting doses of 75 mg every two weeks and 150 mg every four weeks) versus placebo in patients with …
ESG Stroes, J Guyton, M Farnier, N Lepor… - Journal of the American …, 2015 - jacc.org
Background: Statins upregulate PCSK9 and increased PCSK9 accelerates target-mediated
clearance of PCSK9 monoclonal antibodies; this may limit sustained efficacy when …
clearance of PCSK9 monoclonal antibodies; this may limit sustained efficacy when …
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, reality or dream in managing patients with cardiovascular disease
M Alkhalil - Current Drug Metabolism, 2019 - ingentaconnect.com
Background: Statins have been a major keystone in the management of patients with
atherosclerotic cardiovascular disease. The benefits of inhibiting HMG CoA reductase, via …
atherosclerotic cardiovascular disease. The benefits of inhibiting HMG CoA reductase, via …
What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER?
The role of proprotein convertase subtilisin/kexin Type 9 (PCSK9) in the regulation of the low-
density lipoprotein (LDL)-receptor and plasma cholesterol was identified in 2003. 1 This …
density lipoprotein (LDL)-receptor and plasma cholesterol was identified in 2003. 1 This …
[HTML][HTML] PCSK9 inhibitors in a German single-center clinical practice: real-world treatment of patients at high cardiovascular risk over 68 weeks
T Hollstein, U Kassner, T Grenkowitz… - American Journal of …, 2021 - Springer
Aims Several the use of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) for
patients at high/very high cardiovascular risk who are inadequately treated with maximally …
patients at high/very high cardiovascular risk who are inadequately treated with maximally …
Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids
GPS Shantha, JG Robinson - Clinical Pharmacology & …, 2016 - Wiley Online Library
Statins are established therapies for cardiovascular disease prevention and ezetimibe has
recently been shown to modestly reduce cardiovascular events when added to background …
recently been shown to modestly reduce cardiovascular events when added to background …
PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 …
MJ Koren, O Descamps, Y Hata… - The Lancet Diabetes & …, 2024 - thelancet.com
Background Currently available injectable drugs that target proprotein convertase
subtilisin/kexin type 9 (PCSK9) reduce serum LDL cholesterol and improve cardiovascular …
subtilisin/kexin type 9 (PCSK9) reduce serum LDL cholesterol and improve cardiovascular …
Discordant responses of plasma low-density lipoprotein cholesterol and lipoprotein (a) to alirocumab: A pooled analysis from 10 ODYSSEY Phase 3 studies
T Mahmood, J Minnier, MK Ito, QH Li… - European journal of …, 2021 - academic.oup.com
Aims Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors consistently reduce
low-density lipoprotein cholesterol (LDL-C) by 50–60% and lipoprotein (a)(Lp (a)) by 20 …
low-density lipoprotein cholesterol (LDL-C) by 50–60% and lipoprotein (a)(Lp (a)) by 20 …
4CPS-026 Adherence and effectiveness of PCSK9 inhibitors in routine clinical practice
PG Garnica, CS Jiménez, FM Ramos, LG del Valle… - 2019 - ejhp.bmj.com
Background Alirocumab and evolocumab are monoclonal antibodies that belong to a new
class of cholesterol-lowering drugs by inhibiting the proprotein convertase subtilisin/kexin …
class of cholesterol-lowering drugs by inhibiting the proprotein convertase subtilisin/kexin …